Kornimate/medical-research-clean huggingface dataset:
creatine kinase levels and clinical and functional parameters in parajiu-jitsu athletes

Conditions: Healthy; Deficiency Diseases

Summary: introduction: evidence indicates that muscle damage caused by exercise can lead to functional, biochemical and clinical damage. therefore, it is pertinent to perform investigations related to the muscle damage marker, creatine kinase with clinical and functional responses. these outcomes encompass an intrinsic potential for understanding the real magnitude of interpretation of classic signals in athletic environments and monitoring of athletes, contributing to specific actions. objective: to verify the correlation between clinical signs (pain and perception of recovery), functional (muscular strength) and the behavior of ck levels, in the moments following a simulated fight. methods: six male parajiu-jitsu practitioners (34-44 years) were included in the study. the participants attended the collection site 4 times, with a 24-hour interval between sessions, characterizing the following collection moments: baseline, post-exertion, 24, 48 and 72 hours after the simulated fight. data on pain (visual analogue scale - eva), perception of recovery (likert scale), muscle strength (dynamometry) and blood samples for ck analysis were collected. all parameters described were measured at all times of collection. for the analysis of the association between behavior of ck levels, clinical and functional variables, the odds ratio test and 95% confidence interval were used. for the gross values, the pearson test was used according to the normality of the data.

participants will be intentionally allocated into two groups, g1 consisting of professional athletes and g2 consisting of amateur athletes. this division was carried out to guarantee homogeneous stratification between participants with level of conditioning and similar training. the anonymity of the participants will be guaranteed. there will be masking of the participants, investigator and evaluator of the results that were blind to the hypotheses and allocation in groups, adopted in the study. all participants regularly attended the same training center and no sports injuries that might compromise athletic performance will be reported during the survey.

Eligibility criteria:
inclusion criteria: * jiu-jitsu paratroopers were included. to be included in the study participants should report absence of anemia, inflammation, diabetes, cardiovascular disease, and musculoskeletal injuries in the six months prior to data collection. in addition, participants were instructed to refrain from anti-inflammatory drugs, analgesics, alcoholic beverages, and tobacco and did not perform any extra exercise during the study. exclusion criteria: * withdrawal of participants for personal reasons
tolerance and digestibility of a new formula in healthy infants

Conditions: Steatorrhea; Growth

Summary: the great majority of infants formula contain fats exclusively from vegetable oil. nevertheless, the use of both vegetable and dairy lipids is on a real interest to obtain an infant formula closer to the nutritional composition of maternal milk.


Eligibility criteria:
inclusion criteria: * normal growth; * considered as healthy by the investigator according to the medical interrogation and the clinical examination; * receiving exclusively infant formula for at least 15 days. * without any solid food during the month of the study exclusion criteria: * premature born children or small born weights; * children breast-fed or weaned for less than 15 days; * children with solid food * food allergy, particularly in milk proteins allergy , and lactose intolerance ; * tumoral, inflammatory, cardiac, lung, renal, digestive diseases(syndrome of malabsorption); * digestive pathology previous to the inclusion, in particular infectious (rotavirus, gastroenteritis) or functional symptoms (important stomach pains, colicky) having required a lot of change in formula quality; * children under medical treatment (ex: paracetamol).

Keywords: infant formula dairy fat soluble milk protein
predictors of persistence in patients with schizophrenia treated with once-monthly aripiprazole in spain

Conditions: Schizophrenia

Summary: this is an observational, retrospective, non-interventional study that will include schizophrenic patients who were initiated on aom treatment during an schizophrenia-related hospitalisation at least 6 months before data collection and in a real clinical practice setting.

this is an observational, retrospective, non-interventional study that will include schizophrenic patients who were initiated on aom treatment during an schizophrenia-related hospitalisation at least 6 months before data collection and in a real clinical practice setting. data from each patient will be collected after informed consent is obtained (if possible), and will include retrospective information mainly from the index date (start of aom treatment, baseline timepoint) until the last information available in the patient file at the time of data collection (minimum of 6 months after the index date). data will be retrospectively collected from all visits occurring as per clinical practice (usually once-monthly).

Eligibility criteria:
inclusion criteria: 1. adult patients (age ≥ 18 years at the time of aom initiation). 2. diagnosis of schizophrenia according to the diagnostic and statistical manual of mental disorders v available at start of aom treatment, and confirmed by the current investigator. 3. having been hospitalized for an acute psychotic relapse and having been initiated with aom as primary maintenance antipsychotic treatment, in accordance with the terms of the marketing authorisation, during the hospitalisation, at least 6 months before the inclusion and before november 1st 2016 (and up to january 2016 at the earliest). 4. provision of patient informed consent unless a) not required by local regulations, b) it would take a non-reasonable effort\* or c) if the source patient is deceased or untraceable. * a reasonable effort is defined as 3 contact attempts separated by 3 weeks. all efforts to obtain the informed consent, reasonable or not, shall be registered in the medical history of the patient to be used as documental source. if allowable by ethics committees, provision of oral (e.g., by phone) instead of written consent is also possible for patients with retrospective assessment only. exclusion criteria: 1. the patient has a psychiatric disorder other than schizophrenia which is established as the primary diagnosis 2. chronically hospitalized patients at time of aom initiation. 3. patients who receive, after aom initiation, a concomitant oral antipsychotic treatment for more than 4 weeks (with the exception of low dose quetiapine)\* \* low dose quetiapine is acceptable up to a maximum of 150 mg daily only for sedative purposes, but not for the induction of any psychopharmacological effect on mood and/or psychosis. 4. participation in an interventional clinical trial during the retrospective follow-up period.

Keywords: long-acting injectable antipsychotic persistence
cryoablation for obesity management

Conditions: Obesity

Summary: the purpose of this study is to assess the efficacy of cryoablation therapy for the treatment of mild to moderate obesity and test the safety (good and bad effects) of this procedure. the vagus nerve transmits hunger signals from the stomach to the brain, and in response transmits stomach expansion signals from the brain to the stomach. investigators believe that by interrupting this communication, participants could experience less hunger and in turn lose weight.

the purpose of this single arm study is to assess the efficacy of cryoablation therapy for the treatment of mild to moderate obesity and test the safety (good and bad effects) of this procedure. the vagus nerve transmits hunger signals from the stomach to the brain, and in response transmits stomach expansion signals from the brain to the stomach.investigators believe that by interrupting this communication, participants could experience less hunger and in turn lose weight. the rationale for using cryoablation to treat obesity is based on this investigator's experience safely targeting peripheral nerves via ct guidance and treated with thermal ablation in daily clinical practice. the primary objective of this research is to evaluate the feasibility and safety (over time) of percutaneous image guided cryoablation of the posterior vagus nerve in obese patients. the secondary objective consist of temporal evaluation of weight loss and appetite before and after the procedure. this will be analyzed through documentation of weight, and through the implementation of validated outcome instruments.

Eligibility criteria:
inclusion criteria: * body mass index (bmi) 30-35 * weight loss refractory to diet changes or exercise * absence of coagulopathy * ability and willingness of patient to provide written informed consent exclusion criteria: * active infection * underlying congenital anatomic or other spinal anomalies that result in non-conventional anatomy at the gastro-esophageal junction * pregnant or planning to become pregnant * immunosuppression * history or laboratory results indicative of any significant cardiac, endocrine, hematologic, hepatic, immunologic, infectious, metabolic, urologic, pulmonary, gastrointestinal, dermatologic, psychiatric, renal, neoplastic, or other disorder that in the opinion of the principal investigator would preclude the safe performance of cryoablation * uncorrectable coagulopathies * concurrent participation in another investigational trial involving systemic administration of agents or within the previous 30 days * have undergone a previous bariatric surgical intervention

Keywords: cryoablation radiology
homocysteine lowering and atherosclerosis reduction trial (hart)

Conditions: Atherosclerosis; Cardiovascular Disease

Summary: study objective: 1. to evaluate whether combined therapy with folic acid 2.5 mg/day, vitamin b6 50 mg/day and vitamin b12 1000 micrograms/day vs placebo reduces the rate of atherosclerosis progression, as evaluated by quantitative b-mode carotid ultrasound (us).

the hart study is designed as a substudy of the heart outcomes prevention evaluation-2 (hope-2)trial which evaluates the effect of combined therapy ? folic acid and vitamin b6 and b12 on clinical events. the study is designed to enrol 900 study participants randomized to homocysteine lowering therapies or placebo. follow-up will estimate over 5 years. study participants will undergo yearly carotid b-mode ultrasound examinations.

Eligibility criteria:
inclusion criteria:women and men aged ≥ 55 years at high risk for cv events with: (a) documented (cad): i) history of prior mi; ii) stable or unstable angina with documented multivessel cad or strongly positive stress test; iii) multivessel cad and ptca ≥ 6 months prior to randomization; iv) multivessel cabg ≥ 4 years prior to randomization; v) multivessel cad on angiography; (b) documented peripheral vascular disease (pvd): i) previous limp bypass surgery and/or previous peripheral percutaneous transluminal angioplasty and/or previous limp or foot amputation due to pvd.ii) history of intermittent claudication with ankle/arm blood pressure ratio of ≤ 0.80 or with significant arterial stenosis on angiography; (c) documented cerebrovascular disease: i) history of previous ischemic stroke; and (d) diabetes mellitus with ≥ 1 additional major cv risk factor(s). (2) provision of informed consent.(3) adequate baseline carotid us examination. exclusion criteria:1. current use of folic acid supplements \> 200 mg/day. 2. known previous adverse reactions to folic acid, vitamin b6 or b12. 3. planned cardiac, peripheral or cerebrovascular. -

Keywords: atherosclerosis cv risk factors homocysteine cv disease cardiovascular disease
plant protein supplementation within a healthy lifestyle modulates plasma circulating amino acids and improves the health status of overweight individuals

Conditions: Obesity; Metabolic Syndrome; Metabolic Disorder; Inflammation; Immune System and Related Disorders

Summary: a dietary pattern based on mediterranean diet has been reported as healthy for humans, as well as doing aerobic exercise regularly, diminishing the development of potential inflammation in subjects. protein intake has been proposed as nutritional strategy to further improve these positives outcomes in terms of preventing inflammation diseases. in this work, overweight patients followed a mediterranean diet together with aerobic exercise according to who-guidelines and were supplemented with 20 g of hemp protein/day, for twelve weeks. anthropometric and biochemical measures (including analysis of oligoelements), as well as plasma circulating amino acids were evaluated in each patient at the end of the intervention, to assess whether biologically relevant changes could be observed.


Eligibility criteria:
inclusion criteria: * age between 18 and 65 years old * waist circumference ≥94cm in men and ≥88cm in women * met\<4 exclusion criteria: * prediabetic patients on pharmacotherapy * subjects suffering from medical issues (e.g., diabetes or another chronic disease) * smokers * pregnant or lactating women.
maintenance low dose 5'-azacitidine post t cell depleted allogeneic stem cell transplantation for patients with myelodysplastic syndrome and acute myelogenous leukemia with high risk for post-transplant relapse

Conditions: Myelodysplastic Syndromes (MDS); Acute Myelogenous Leukemia (AML)

Summary: the purpose of this study is to learn if 5'-azacitidine will help to lower the risk of the disease coming back after a stem cell transplant in patients with mds and aml. this study will also be looking at the side effects of this medicine. 5'-azacitidine is an fda approved drug for treatment of mds and aml, as well as patients whose disease came back after transplant, where it helped going into remission. it is unclear if 5'-azacitidine can prevent the disease from coming back after transplant. this study will help show if getting 5'-azacitidine soon after transplant can lower the risk of your disease coming back.


Eligibility criteria:
inclusion criteria: patients who have undergone t cell depleted allogeneic hematopoietic stem cell transplantation at mskcc for: * de novo myelodysplastic syndromes (mds): ipss-1 with poor risk cytogenetics or higher ipss. * acute myelogenous leukemia (aml) in first remission that required more than 1 cycle of treatment to achieve remission or with the following cytogenetic abnormalities: flt3 mutation, deletion/monosomy of chromosome 5 or 7, mll gene rearrangement, or more than or equal to 3 cytogenetics abnormalities. also patients in second or greater remission. * patients with secondary mds/aml. * patients will be considered eligible for the study if after transplant they achieved hematologic (\<5% blasts) and cytogenetic remission. * patients will be eligible to enter the study between 60-120 days post transplant. * age: pediatrics and adults patients - 1 year old-75 years old. * karnofsky performance status \>=60% for patients \>16yo and lansky performance status \>=60% for patients ≤16yo * stable blood counts (anc\>1000/ul, hb\>8gr/dl, plt\>50,000/ ul) not supported by transfusions. * renal: serum creatinine \<1.5 uln * hepatic: \<3xuln alt and \<1.5 total serum bilirubin, unless there is congenital benign hyperbilirubinemia. * cardiac: adequate cardiac function measured by lvef\>50%. if asymptomatic, pretransplant echocardiogram is adequate. if symptomatic, echocardiogram needs to be repeated. * each patient must be willing to participate as a research subject and must sign an informed consent form. exclusion criteria: patients will be excluded from the trial if at time of enrollment: * active uncontrolled bacterial, fungal or viral infection. * evidence of uncontrolled graft-versus-host disease. * pulmonary: new onset hypoxia * known or suspected hypersensitivity to 5'-azacitadine or mannitol. * evidence of residual disease either by increased blasts count (\>5%) or persistence of previous known cytogenetics abnormalities. * peripheral blood neutrophil chimerism: less than 95% donor.

Keywords: 5'-azacitidine stem cell transplant 13-192
lidocaine infusion in pancreatic cancer

Conditions: Pancreatic Cancer

Summary: this study elucidates the effects of the intravenous (iv) lidocaine infusion on the biology of pancreatic circulating tumor cells (ctcs) isolated from patients undergoing robotic pancreatectomy for all types of pancreatic cancer. a prospective randomized controlled double blinded trial design will be used for the proposed study.

the primary objective of this study is to determine the effect of iv lidocaine infusion on various enzymatic activities and associated pathways in isolated ctcs as well as the number of ctcs during the perioperative period in patients undergoing robotic pancreatectomy for pancreatic cancer. it is expected that by downregulating the pathways by lidocaine might affect the enzymatic activity in those ctcs as well as the number of ctcs in the circulation. a prospective randomized controlled double blinded trial design will be used for the proposed study. patients undergoing robotic pancreatectomy for pancreatic cancer will be randomized (ratio 1:1) into two groups: one group will receive a 24-h normal saline infusion and the second group will receive a 24-h lidocaine infusion. blood samples will be collected in different times perioperatively in order to evaluate the objectives of the study.

Eligibility criteria:
inclusion criteria: 1. has histologically or cytologically confirmed adenocarcinoma of the pancreas that is considered resectable as well as other types of pancreatic cancer (malignant endocrine and exocrine tumors) 2. has measurable disease, defined as at least 1 tumor that fulfills the criteria 3. patients diagnosed with resectable cancer, but upon initial phase of surgical exploration found to have metastatic disease 4. has read, understood and signed the informed consent form (icf) approved by the independent review board/independent ethics committee (irb/iec) 5. prior systemic treatments for metastatic disease are permitted, including targeted therapies, biologic response modifiers, chemotherapy, hormonal therapy, or investigational therapy. exclusion criteria: 1. has american society of anesthesiologists (asa) physical status \> 3 2. has hypersensitivity or allergy to amide-linked local anesthetics 3. has a second or third degree heart block 4. has severe sinoatrial block 5. is currently being treated with any of the following class i antiarrhythmic drugs; quinidine, flecainide, disopyramide, or procainamide 6. has been treated with amiodarone in the past 7. has adams-stoke syndrome 8. has wolff-parkinson-white syndrome 9. has a history of blood clots, pulmonary embolism, or deep vein thrombosis unless controlled by anticoagulant treatment 10. has a known history of human immunodeficiency virus (hiv) positivity or untreated and uncontrolled hepatitis b or c

Keywords: pancreas pancreatic cancer lidocaine enzymatic activity cytokines chemokines gene expression
nyu ovarian cancer early detection program blood and genetics

Conditions: Ovarian Cancer

Summary: improving current strategies for detection of early stage disease can impact favorably on long-term survival of women with ovarian cancer. to reduce the morbidity and mortality of ovarian cancer, screening for this disease must detect early stage disease rather than advanced stage disease. thus the challenge for the future is to identify and develop highly sensitive and specific tumor markers that can be applied to population-based screening for the early detection of ovarian cancer.

the aim of nyu ovarian cancer early detection program is to establish an effective, early detection program employing state-of-the-art science and technology in collaboration with other nationally recognized clinicians and scientists. this proposed research study will foster collaboration between clinicians and scientists that will facilitate the rapid identification of a set of molecular, biochemical, functional, and genetic markers which can be employed to effectively detect and manage ovarian cancer and other gynecological malignancies.

Eligibility criteria:
inclusion criteria: women enrolled in the nyu ovarian cancer early detection program have at least one of the following risk factors: * a personal history of breast cancer * one or more first degree relatives (mother, sister, daughter) with ovarian cancer * multiple family members with either breast and/or ovarian cancer * a personal history of a positive brca1 or brca2 genetic test result * a close relative with a positive brca1 or brca2 genetic test result * a personal history of colon or endometrial cancer with at least two relatives with a lynch/hnpcc-associated cancer (colorectal, endometrial, small bowel, ureter, or renal pelvis cancer) * synchronous or metachronous endometrial and colorectal cancer * a personal history of a mismatch repair gene mutation (mlh1, msh2, msh6 or pms2) * a close relative with a mismatch repair gene mutation (mlh1, msh2, msh6 or pms2) * a personal history of colorectal or endometrial cancer with a mismatch repair defect (ie. microsatellite instability (msi) or immunohistochemical loss of expression of mlh1, msh2, msh6, or pms2) * the use of fertility drugs for more than one year

Keywords: women with increased risk for developing ovarian cancer early detection biomarker for ovarian cancer
interscalene brachial plexus block washout to reverse inadvertent phrenic nerve blockade

Conditions: Anesthesia, Local; Phrenic Nerve Paralysis; Upper Extremity Injury; Phrenic Nerve Palsy on the Left; Phrenic Nerve Palsy on the Right

Summary: one of the most frequently performed peripheral nerve blocks (the injection of local anesthetic near nerves to block sensation/ movement to a specific part of the body) is the interscalene brachial plexus block for upper extremity surgeries. this type of block can unmask underlying respiratory issues such as shortness of breath due to a well-known and typically insignificant side effect of temporary diaphragmatic paralysis. the nerve block may be able to use saline solution to wash out the local anesthetic and potentially reverse this respiratory side effect. specifically, the goal of this study is to determine if the injection of saline through the nerve block catheter reverses blockade of the phrenic nerve supplying the diaphragm, without affecting the ability of the nerve block to provide pain control after surgery.


Eligibility criteria:
inclusion criteria: * all adult patients (18 years and over) scheduled for surgery requiring a continuous interscalene brachial plexus nerve block catheter as part of their anesthetic care. exclusion criteria: * concomitant life-threatening injuries and other concomitant injuries causing significant pain * pregnant * any condition impairing patient's ability to consent to participation in study, and an existing condition contraindicating a nerve block, i.e. nerve injury, existing bleeding disorder, infection in the vicinity of the block, and patient refusal.
computerized intervention for distress intolerance

Conditions: Cannabis Use Disorder

Summary: this study evaluates the impact of a computerized distress intolerance intervention relative to a control intervention on cannabis use-related behavior and neurophysiology.

distress intolerant cannabis users were randomized to a computerized distress intolerance intervention or a control intervention. primary and secondary outcomes consist of the treatment target, cannabis use-related behavior, and theoretically-relevant neurophysiological processes (i.e., cannabis cue reactivity, response inhibition).

Eligibility criteria:
inclusion criteria: * distress intolerance index score \>= 20 * average cannabis use frequency in the past year \>= 2-3/week exclusion criteria: * current suicidal ideation * history of psychotic symptoms * bipolar-spectrum disorder without stabilization on medication for \>= 3 months * change in psychotropic medication in the past month * current cbt for internalizing or substance use disorders

Keywords: distress intolerance stress